Company: ISRG
Filing Date: 2025-03-14
Form Type: DEF 14A
Source: 0001035267-25-000098
Chunk: 3

Company: INTUITIVE SURGICAL INC
Filing Date: 2025-03-14
Form: DEF 14A
Chunk 3
---
 for Intuitive. We made meaningful progress on our mission, while taking important steps to position the business for the future.

#### Financial Results Demonstrate Business Momentum
On behalf of the Board of Directors, I want to extend gratitude to our employees for their dedication and hard work, which enabled Intuitive to deliver $8.35 billion in full year revenue in 2024, an increase of 17% from the prior year. As a result of improved product margins, driven by our continued innovation and supply chain efficiencies, the team has increased our net income by 29% from 2023. We have also successfully expanded the reach and impact of our products and procedures, with da Vinci surgical system placements up 11% compared to 2023. More than 2.7 million procedures were performed by our customers using da Vinci and Ion systems in 2024, with more than 17 million total procedures performed to date.

These results were driven by continued execution against our strategic priorities:

• Advancing innovation and patient care through successful launches of new platforms and regulatory clearances for new and expanded indication areas for current platforms;

• Increasing adoption for focused procedure areas by country through training, commercial activities, and market access efforts;

• Continuing to focus on quality and gross margin improvement in our global operations; and

• Seeking to capitalize on opportunities for efficiency as we invest to meet the need for minimally invasive care at industrial scale.

#### Customer and Patient Focus
Since our founding, Intuitive has been dedicated to combining leading technology with clinical expertise to provide surgeons, hospitals, and healthcare systems with products and services that allow them to provide life-enhancing, minimally invasive care. We focus on what matters most to our customers and the patients they treat, by aligning our efforts to their goals as expressed by the Quintuple Aim, which is: seeking to deliver better patient outcomes and improving patient and care team experiences, while lowering treatment costs, reducing the duration of hospital admissions, and enabling expanded access to care.

This long-term commitment to meeting the needs of customers and patients informs our priorities. We focus on excellence in product innovation, quality and availability, and delivering a world-class customer experience through our ecosystem of training, data analytics, and other services and support. These efforts seek to advance what is possible in minimally invasive care and help customers reliably and repeatably deliver care in the most resource-efficient manner possible.

In 2024, we launched da Vinci 5, our most advanced and integrated surgical system to date. Da Vinci 5 is designed